NASDAQ:CYTR - CytRx Corporation
$0.61
 $0.01
+1.71%
2:30PM EDT
2019-02-15
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CYTR     avg for
industry  
  avg for
sector  
42 stocks weight:  30. 48   0. 00   0. 00  
42 stocks rank:  3. 31 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  

quick ratio:  2. 94   5. 37   1. 81  
current ratio:  3. 06   5. 69   2. 19  

target price low:  0. 45   88. 97   117. 82  
target price avg:  0. 45   115. 19   141. 96  
target price high:  0. 45   143. 40   163. 16  
1-yr high:  2. 11   124. 30   142. 77  
last close:  0. 60   101. 85   127. 84  
50-day avg:  0. 54   98. 27   122. 46  
200-day avg:  0. 96   99. 72   122. 70  
1-yr low:  0. 36   78. 19   100. 16  
volume:  124. 70 K 2. 38 M 4. 64 M
50-day avg volume:  151. 51 K 3. 31 M 4. 94 M
200-day avg volume:  182. 62 K 3. 23 M 4. 28 M

1-day return:  3. 45 % 0. 22 % 0. 48 %
this week return:  3. 45 % 1. 77 % 2. 01 %
12-wk return:  1. 69 % 6. 56 % 3. 33 %
52-wk return:  -63. 04 % -2. 23 % 14. 35 %

enterprise value (EV):  -4. 49 M 55. 17 B 104. 51 B
market cap:  20. 06 M 49. 01 B 96. 46 B
EBITDA:  -14. 57 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 31   -91. 79   2. 29  
enterprise/revenue (EV/R):  -12. 82   29. 84   23. 39  
total revenue:  350. 00 K 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -14. 84 M 2. 37 B 3. 58 B

shares outstanding:  33. 64 M 607. 99 M 1. 22 B
shares:  28. 92 M 605. 53 M 1. 15 B
shares short:  316. 87 K 11. 62 M 12. 55 M
shares short prior month:  318. 31 K 11. 95 M 13. 44 M
short ratio:  2. 47   4. 82   3. 10  
short % of float:  0. 97 % 6. 19 % 2. 82 %
total cash/share:  0. 73   12. 02   11. 46  
total cash:  24. 67 M 7. 41 B 7. 37 B
free cash flow:  -17. 59 M 95. 99 M 2. 04 B
operating cash flow:  -15. 06 M 164. 74 M 3. 04 B

book value:  0. 66   14. 43   28. 26  
price/book:  0. 90   -1. 57   -2. 97  
gross profits:  100. 00 K 8. 28 B 18. 09 B
operating margins:  -4317. 84 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  100. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -32. 80 % --- ---
1-yr mean volatility:  -0. 28 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 50   3. 03   4. 09  
forward EPS:  -0. 24   4. 33   6. 99  
P/E:  -1. 19   6. 11   26. 91  
forward P/E:  -2. 43   8. 38   10. 48  
PE/G:  0. 03   0. 37   5. 61  
growth:  -42. 04 % 683. 72 % 104. 79 %
earnings high:  -0. 07   1. 27   1. 66  
earnings avg:  -0. 07   1. 01   1. 53  
earnings low:  -0. 07   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -22. 87 % -3. 27 % 3. 81 %
return on equity:  -67. 71 % 107. 48 % 27. 82 %
revenue/share:  0. 01   14. 68   59. 83  

beta (1yr vs S&P500):  0. 81   1. 21   0. 93  
sharpe (1yr):  -0. 99   0. 06   0. 98  

held % insiders:  8. 49 % 6. 46 % 3. 21 %
held % institutions:  10. 82 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CYTR
.    + 0.272 =         0.272 :: INITIAL WEIGHT
.  + 459.993 =       460.265 :: inverse volume-to-price addition
.    + 0.045 =        460.31 :: spline projection addition
.  - 169.528 =       290.782 :: poor performance penalty
.    x 0.609 =       177.221 :: one-year gains+dividend factor
.    x 6.304 =      1117.268 :: 13 weeks' performance factor
.    x 1.492 =       1667.51 :: industry recommendation factor
.    x 0.998 =      1663.697 :: return on assets factor
.    x 0.993 =      1652.433 :: return on equity factor
.    x 2.538 =      4193.834 :: current ratio factor
.    x 1.231 =      5161.429 :: quick ratio factor
.    x 1.185 =      6117.673 :: short ratio factor
.    x 2.009 =     12290.625 :: price-to-book factor
.    x 5.649 =      69427.83 :: EBITDA multiple factor
.    x 1.095 =     76035.694 :: 5-day avg > 50-day avg
.     x 2.17 =    164981.734 :: P/E weight
.    x 2.209 =    364437.904 :: PE/G factor
.    x 1.486 =    541535.642 :: beta factor
.    x 0.991 =    536780.831 :: sharpe factor
.     x 0.95 =     509941.79 :: target low factor
.    x 0.911 =    464749.375 :: target mean factor
.     x 0.95 =    441511.907 :: target high factor
.    x 1.066 =    470480.742 :: industry 12-weeks return
.    x 0.999 =    470129.648 :: overall "drift" factor
.    x 0.998 =    469412.335 :: largest single-day jump factor
.     x 0.06 =     28311.962 :: low price factor
.      x 1.0 =     28313.863 :: factor hist industry gain for week 06
.   cubeRoot =        30.479 :: reduced for readability
.                     30.479 :: FINAL WEIGHT for NASDAQ:CYTR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org